We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter International (BAX) Up 6.7% Since Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for Baxter International Inc. (BAX - Free Report) . Shares have added about 6.7% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Baxter International Q1 Earnings Beat, FY17 View Up
Baxter International reported first-quarter 2017 adjusted earnings of $0.58 per share, which surpassed the Zacks Consensus Estimate by $0.07 and was way better than the year-ago figure of $0.36.
The figure was also above the company’s guidance of $0.50 to $0.52. Interestingly, over the last four trailing quarters, the company posted positive earnings surprises, the average being 19.75%.
The company posted sales of $2.47 billion, marginally beating the Zacks Consensus Estimate of $2.43 billion. At constant currency (cc), revenues increased 5% on a year-over-year basis.
Adjusting for the impact of foreign exchange and increased competition for the company’s cyclophosphamide, Baxter’s sales were up 7% on a year-over-year basis. U.S. sales were up 1% year over year to $1.1 billion. International sales increased 1% to almost $1.4 billion.
In the first quarter, Baxter acquired Wound Care Technologies, which is complementary to the company’s surgical portfolio. The company also entered into a strategic partnership with Scinopharm, one of the world’s leading active pharmaceutical ingredient (API) manufacturers.
Segment Details
Hospital products: Sales at this segment climbed 7% at cc on a year-over-year basis to $1.6 billion. Solid U.S. sales of IV therapies, IV access sets, and select anesthesia and critical care products were the key catalysts. Growing adoption of Baxter’s ‘parenteral nutrition therapies’ and international bio-surgery products also drove sales at this segment.
Renal products: Sales increased 1% at cc to $$896 million at this segment. Renal sales were driven by peritoneal dialysis products and increased global demand for continuous renal replacement therapies. Also, solid demand for the company’s Automated Peritoneal Dialysis (APD) cyclers – AMIA in the U.S. and HOMECHOICE CLARIA in international markets – boosted sales.
Guidance
For full-year 2017, Baxter projects earnings in the band of $2.20 to $2.28 per share, up from the previously issued range of $2.10 to $2.18 (from continuing operations, before special items). Furthermore, the company expects sales growth in the band of 2% to 3% at cc.
For the first quarter of 2017, Baxter estimates sales growth of about 2% at cc. Adjusted earnings are forecasted in the range of $0.55 to $0.57 per share.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions.
At this time, the stock has a subpar Growth score of 'D', while its Momentum is lagging a bit with 'F'. However, the stock was allocated a grade of 'B' on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM score of 'D'. If you aren't focused on one strategy, this score is the one you should be interested in.
The company's stock is suitable solely for value based on our styles scores.
Outlook
The stock has a Zacks Rank #2 (Buy). We are expecting an above average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Baxter International (BAX) Up 6.7% Since Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Baxter International Inc. (BAX - Free Report) . Shares have added about 6.7% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Baxter International Q1 Earnings Beat, FY17 View Up
Baxter International reported first-quarter 2017 adjusted earnings of $0.58 per share, which surpassed the Zacks Consensus Estimate by $0.07 and was way better than the year-ago figure of $0.36.
The figure was also above the company’s guidance of $0.50 to $0.52. Interestingly, over the last four trailing quarters, the company posted positive earnings surprises, the average being 19.75%.
The company posted sales of $2.47 billion, marginally beating the Zacks Consensus Estimate of $2.43 billion. At constant currency (cc), revenues increased 5% on a year-over-year basis.
Adjusting for the impact of foreign exchange and increased competition for the company’s cyclophosphamide, Baxter’s sales were up 7% on a year-over-year basis. U.S. sales were up 1% year over year to $1.1 billion. International sales increased 1% to almost $1.4 billion.
In the first quarter, Baxter acquired Wound Care Technologies, which is complementary to the company’s surgical portfolio. The company also entered into a strategic partnership with Scinopharm, one of the world’s leading active pharmaceutical ingredient (API) manufacturers.
Segment Details
Hospital products: Sales at this segment climbed 7% at cc on a year-over-year basis to $1.6 billion. Solid U.S. sales of IV therapies, IV access sets, and select anesthesia and critical care products were the key catalysts. Growing adoption of Baxter’s ‘parenteral nutrition therapies’ and international bio-surgery products also drove sales at this segment.
Renal products: Sales increased 1% at cc to $$896 million at this segment. Renal sales were driven by peritoneal dialysis products and increased global demand for continuous renal replacement therapies. Also, solid demand for the company’s Automated Peritoneal Dialysis (APD) cyclers – AMIA in the U.S. and HOMECHOICE CLARIA in international markets – boosted sales.
Guidance
For full-year 2017, Baxter projects earnings in the band of $2.20 to $2.28 per share, up from the previously issued range of $2.10 to $2.18 (from continuing operations, before special items). Furthermore, the company expects sales growth in the band of 2% to 3% at cc.
For the first quarter of 2017, Baxter estimates sales growth of about 2% at cc. Adjusted earnings are forecasted in the range of $0.55 to $0.57 per share.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions.
Baxter International Inc. Price and Consensus
Baxter International Inc. Price and Consensus | Baxter International Inc. Quote
VGM Scores
At this time, the stock has a subpar Growth score of 'D', while its Momentum is lagging a bit with 'F'. However, the stock was allocated a grade of 'B' on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM score of 'D'. If you aren't focused on one strategy, this score is the one you should be interested in.
The company's stock is suitable solely for value based on our styles scores.
Outlook
The stock has a Zacks Rank #2 (Buy). We are expecting an above average return from the stock in the next few months.